Notice Regarding Revision of Earnings Guidance for Fiscal Year Ending March 2026

Details of Earnings Guidance Revision

The full-year consolidated earnings guidance for the fiscal year ending March 2026 has been revised, with revenue set at 449.0 billion yen (4.7% increase from previous forecast), operating income at 108.0 billion yen (10.2% increase), and net income attributable to owners of parent at 102.0 billion yen (10.9% increase). Core operating income has also been raised to 107.0 billion yen (10.3% increase).

Reasons and Background for the Revision

The increase in revenue reflects stronger-than-expected sales of the overactive bladder treatment ‘Gemtesa’ and other products in the North American segment, as well as the impact of yen depreciation. Core operating income was revised upward from the previous forecast due to higher gross profit gains, despite selling, general and administrative expenses and R&D expenses expected to be slightly below previous forecasts when excluding the yen depreciation effect. Consequently, operating income and net income were also revised upward.